Weight loss drugs like Ozempic, while transformative in combating obesity, have been linked to irreversible vision impairment ...

“The real stroke of brilliance is the notion that you make the cell younger, and then it would be more resilient to injury,” ...

Semaglutide use in patients with type 2 diabetes moderately increases the risk of nonarteritic anterior ischemic optic neuropathy.

Non-arteritic anterior ischemic optic neuropathy (NAION) - also known as a "eye stroke" - typically causes sudden vision loss in one eye. It occurs from a lack of sufficient blood flow to the ...

But, after getting a CT-scan and seeing a neuro-ophthalmologist, it was revealed he had non-arteritic anterior ischemic optic neuropathy (NAION), a condition in which the loss of blood flow to the ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION).

Semaglutide was tied to nonarteritic anterior ischemic optic neuropathy (NAION) risk vs. nonuse in adults with type 2 diabetes. New semaglutide users did not have higher NAION risk vs. most other ...

People taking the weight-loss drug semaglutide could be at a slightly increased risk for a potentially blinding eye condition that affects the optic nerve, a new study says. Patients on ...

However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve.